MaxCyte, Inc. and Lion TCR announced the signing of a strategic platform license (SPL). This partnership will enhance MaxCyte's presence in Asia, with anticipated expansion into the US and European markets. Under the terms of the agreement, Lion TCR obtains worldwide non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation®?

technology and ExPERT?? platform. In return, MaxCyte is entitled to receive annual license fees and program-related revenue.

Lion's proprietary TCR-T cell therapy platform is supported by robust research, in collaboration with renowned laboratories, in the areas of autologous T cells and 'off-the-shelf' technologies. The company's TCR-T cell therapy harnesses the patient's own immune system to fight against viral infections and cancers. The company is conducting ongoing clinical trials against hepatocellular carcinoma to evaluate the safety and efficacy of its TCR-T cells.

Lion has engineered Hepatitis B virus (HBV)-specific T cells to recognize HBV-expressing tumor cells and achieve targeted killing, which is key as HBV is a major cause of hepatocellular carcinoma. Lion TCR is MaxCyte's 24th strategic partnership overall, each of which generates pre-commercial milestone revenue and the vast majority of which include sales-based payments.